Price T Rowe Associates Inc. MD Cuts Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Price T Rowe Associates Inc. MD reduced its stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 96.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 14,182 shares of the company’s stock after selling 365,762 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Black Diamond Therapeutics were worth $31,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of BDTX. Barclays PLC increased its holdings in shares of Black Diamond Therapeutics by 201.9% in the 3rd quarter. Barclays PLC now owns 78,151 shares of the company’s stock valued at $339,000 after acquiring an additional 52,265 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Black Diamond Therapeutics during the fourth quarter valued at $42,000. Rhumbline Advisers raised its position in Black Diamond Therapeutics by 14.9% during the fourth quarter. Rhumbline Advisers now owns 56,135 shares of the company’s stock valued at $120,000 after buying an additional 7,290 shares during the period. Bank of New York Mellon Corp raised its position in Black Diamond Therapeutics by 46.1% during the fourth quarter. Bank of New York Mellon Corp now owns 207,074 shares of the company’s stock valued at $443,000 after buying an additional 65,341 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Black Diamond Therapeutics in the 4th quarter worth about $53,000. Institutional investors and hedge funds own 95.47% of the company’s stock.

Insider Buying and Selling at Black Diamond Therapeutics

In other Black Diamond Therapeutics news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the firm’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the transaction, the insider now owns 2,733,547 shares in the company, valued at $5,658,442.29. This trade represents a 67.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 8.87% of the company’s stock.

Black Diamond Therapeutics Trading Up 1.0%

BDTX stock opened at $1.95 on Monday. The firm has a market cap of $110.52 million, a PE ratio of -1.47 and a beta of 2.63. The business’s 50-day moving average price is $1.60 and its two-hundred day moving average price is $2.11. Black Diamond Therapeutics, Inc. has a 1-year low of $1.20 and a 1-year high of $6.75.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.03. On average, analysts forecast that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Stifel Nicolaus lowered their price objective on Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, March 7th. HC Wainwright lifted their price objective on Black Diamond Therapeutics from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, March 18th. Finally, Wedbush reissued an “outperform” rating and issued a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday, March 19th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $14.60.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.